Eculizumab-related progressive multifocal leukoencephalopathy
Loading...
Official URL
Full text at PDC
Publication date
2015
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer
Citations
Exportar
Citation
Gómez-Cibeira E, Ivanovic-Barbeito Y, Gutiérrez-Martínez E, Morales E, Abradelo M, Hilario A, Ramos A, Ruiz-Morales J, Villarejo-Galende A. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology. 2016 Jan 26;86(4):399-400. doi: 10.1212/WNL.0000000000002312. Epub 2015 Dec 30. PMID: 26718572; PMCID: PMC4776092.
Abstract
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the CNS caused by reactivation of the polyomavirus JC (JCV). In the context of immunosuppression, JCV can reactivate and spread to brain infecting oligodendrocytes. Eculizumab is a first-in-class humanized monoclonal antibody developed to target the cleavage of C5, preventing the release of C5a and activation of the terminal complement pathway. It has been shown to be effective in the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). Eculizumab can impair neutro- phil and monocyte functions and predispose to encapsulated bacteria infections. We report the novel finding of PML in a patient receiving eculizumab.